Source: International Congress 2019 – Beyond continuous positive airway pressure treatment
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
K. Flores (Rome, Italy), F. Viccaro (Rome, Italy), M. Aquilini (Rome, Italy), F. Ronchetti (Rome, Italy), S. Scarpino (Rome, Italy), A. Di Napoli (Rome, Italy), G. Scafetta (Rome, Italy), P. Palange (Rome, Italy), A. Ricci (Rome, Italy). Serum and mucosal brain derived neurotrophic factor (BDNF) in severe obstructive sleep apnea syndrome (OSAS). Effects of CPAP treatment on BDNF serum levels.. 4177

Member's Comments

No comment yet.

Related content which might interest you: Rapid fall of brain-derived neurotrophic factor (BDNF) serum and plasma levels following sleep apnea treatment Source: Eur Respir J 2005; 26: Suppl. 49, 354s Year: 2005 The impact of serum leptin and soluble leptin receptor (sOB-R) levels on respiratory chemosensitivities in obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 413s Year: 2006 Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004 Plasma levels of TNF in obstructive sleep apnea syndrome (OSA) before and after surgical intervention Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012 Effect of continuous positive airway pressure treatment (CPAP) in angiogenic growth factors‘ expression in patients with COPD and obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases Year: 2010 Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients Source: Eur Respir J 2001; 18: Suppl. 33, 334s Year: 2001 Plasma homocysteine (Hcy) levels in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea Year: 2007 Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004 Plasma endothelin-1 (ET-1) levels in obstructive sleep apnea (OSA) patients and effect of continouous positive airway pressure (CPAP) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Plasma vascular endothelial growth factor levels in patients with obstructive sleep apnea hypopnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 564s Year: 2004 Association of IL-6 and TNFα and leptin receptor (LEPR) gene polymorphism with IL-6 and TNFα serum level in obstructive sleep apnea syndrome (OSAS) patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007 Plasma levels of vascular endothelial growth factor in children with sleep-disordered breathing Source: Annual Congress 2005 - Sleep apnoea in children Year: 2005 Evaluation of long-term effect of continuous positive airway pressure (CPAP) therapy on reduction of high sensitivity C-reactive protein (HSCRP) for patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 357s Year: 2005 The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005 BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Relationship between obstructive sleep apnoea syndrome (OSAS) and the levels of endothelial progenitor cells (EPC) in patients with acute stroke Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea Year: 2011 Study of inflammatory markers (C-reactive protein & tumor necrosis factor-α) in moderate to severe obstructive sleep apnea hypopnea syndrome (OSAHS) and their response to treatment with nasal continuous positive airway pressure (nCPAP) Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009 Effect of continuous positive airway pressure treatment on elevated levels of C-reactive protein in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004 C-reactive protein (CRP) levels in obstructive sleep apnea (OSA) patients and relation to severity of OSA Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea Year: 2011 Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment Source: Eur Respir J 2003; 22: 251-257 Year: 2003